Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer

Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy.

Evaluating the effect of genomically informed treatment decision-making on long-term oncological outcomes for individuals diagnosed with intermediate …

Accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: a randomised phase III trial

Working Out M0 Bipolar Androgen Therapy (WOMBAT)

Novel Integration of new prostate radiation therapy schedules with adjuvant androgen deprivation